Jump to content

Tinglong Dai

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Ingenuity (talk | contribs) at 18:33, 15 August 2022 (Added {{Undisclosed paid}} tag). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Tinglong Dai
NationalityAmerican
Academic career
FieldOperations management
Health care analytics
Supply chain management
InstitutionJohns Hopkins University
Alma materCarnegie Mellon University (PhD, 2013)
Hong Kong University of Science and Technology (MPhil, 2006)
Tongji University (BEng, 2004)
Doctoral
advisor		Sridhar Tayur
Katia Sycara
Websitecarey.jhu.edu/faculty/faculty-directory/tinglong-dai-phd

Tinglong Dai is a Professor of Operations Management and Business Analytics at the Carey Business School, Johns Hopkins University, with expertise in the areas of healthcare analytics, global supply chains, the interfaces between marketing and operations, and human–AI interaction.[1] Dai's research primarily examines the health care ecosystem using analytics approaches, with a focus on behavioral, incentive, and policy issues related to healthcare operations management.[2][3]

In particular, he has worked extensively on the analysis and design of vaccine supply chains, including influenza vaccine contracting,[4] COVID-19 vaccination,[5][6][7][8] and next-generation vaccine manufacturing.[9] He is considered "one of the nation's foremost experts on vaccine distribution."[10]

Career

Tinglong Dai earned his B.Eng. in Automation from Tongji University in 2004, MPhil in Industrial Engineering from the Hong Kong University of Science and Technology in 2006, and PhD in Operations Management and Robotics from Carnegie Mellon University in 2013, with Sridhar Tayur and Katia Sycara as his dissertation co-chairs.

Dai joined the faculty of Johns Hopkins in 2013 as an assistant professor in Carey Business School, was promoted to an associate professor in 2018, and became a tenured full professor in 2021. The business education website Poets & Quants named him one of the World's Best 40 Under 40 Business School Professors.[11][12] For his multidisciplinary research on healthcare analytics and artificial intelligence, he won the Johns Hopkins Discovery Award three times, in 2015, 2020, and 2022, respectively.[13][14][15]

At Johns Hopkins University, Dai holds a joint faculty appointment in the Johns Hopkins School of Nursing. He serves on the leadership team of the university-wide Hopkins Business of Health Initiative[16] and the executive committee of the Institute for Data Intensive Engineering and Science.[17]

He has served on the editorial boards of Manufacturing & Service Operations Management, Production and Operations Management, Naval Research Logistics, and Health Care Management Science.

Academic work

Dai is known for his work in behavioral, incentive, and policy issues in managing healthcare operations.[18] His work has found applications in a variety of settings, most notably in vaccine supply chains,[4][6] vaccination,[5] organ donation,[19] organ transplantation,[20] diagnostic decision-making,[21][22] and incorporating AI into healthcare delivery.[23] His research has appeared in leading academic journals, including Management Science, Manufacturing & Service Operations Management, Marketing Science, and Operations Research, and has won First Place in the Production and Operations Management Society's College of Healthcare Operations Management's Best Paper Competition, the INFORMS Public Sector Operations Research Best Paper Award, and the INFORMS Pierskalla Award for Best Paper Award in Healthcare (runner-up), among other best paper awards.[1]

Throughout the COVID-19 pandemic, Dai has written and spoken extensively about the importance of and means to improving the resiliency and transparency of the U.S. personal protective equipment supply chain.[24][25][26][27][28][29][30][3] According to a 2021 Fortune Magazine article, "Dai has relentlessly advocated for regulations making supply chains more transparent."[31]

Related to the interfaces between marketing and operations, Dai's work is among the first to introduce inventory and supply chain constraints to the study of sales force compensation, through the study of a series of moral-hazard principal–agent problems.[32][33][34][35]

He co-edited (with Sridhar Tayur) the first desk reference on healthcare analytics, Handbook of Healthcare Analytics: Theoretical Minimum for Conducting 21st Century Research on Healthcare Operations, which was published by John Wiley & Sons in 2018.[36]

Media coverage

Dai has been quoted hundreds of times in the popular media, including the Associated Press,[37][38] Bloomberg News,[39] CNN,[40][41] Fortune,[42][43][44][45][46] The New York Times,[47][48][49][50][51][52][53][54] NPR,[55] USA Today,[56][57][58] The Wall Street Journal,[59] and The Washington Post,[60][61] and has appeared on national and international TV, such as CNBC,[62] PBS NewsHour,[3] and Sky News. In 2021, Poets & Quants named him one of the World's Best 40 Under 40 Business School Professors.[11][12]

Publications

Book

  • Dai, Tinglong; Tayur, Sridhar, eds. (2018). Handbook of Healthcare Analytics: Theoretical Minimum for Conducting 21st Century Research on Healthcare Operations. John Wiley & Sons, Inc. ISBN 978-1-119-30094-6.

Journal Publications

  • Wang, Guihua; Zheng, Ronghuo; Dai, Tinglong (2021-07-09). "Does Transportation Mean Transplantation? Impact of New Airline Routes on Sharing of Cadaveric Kidneys". Management Science. 68 (5): 3660–3679. doi:10.1287/mnsc.2021.4103. S2CID 237797406.
  • Dai, Tinglong; Ke, Rongzhu; Ryan, Christopher Thomas (2021). "Incentive Design for Operations-Marketing Multitasking". Management Science. 67 (4): 2211–2230. doi:10.1287/mnsc.2020.3651. S2CID 234602078.
  • Dai, Tinglong; Tayur, Sridhar (2020). "OM Forum—Healthcare Operations Management: A Snapshot of Emerging Research". Manufacturing & Service Operations Management. 22 (5): 869–887. doi:10.1287/msom.2019.0778. S2CID 169467315.
  • Dai, Tinglong; Zheng, Ronghuo; Sycara, Katia (2020). "Jumping the Line, Charitably: Analysis and Remedy of Donor-Priority Rule". Management Science. 66 (2): 622–641. doi:10.1287/mnsc.2018.3266. S2CID 54028044.
  • Dai, Tinglong; Singh, Shubhranshu (2020). "Conspicuous by Its Absence: Diagnostic Expert Testing Under Uncertainty". Marketing Science. 39 (3): 540–563. doi:10.1287/mksc.2019.1201. S2CID 214449699.
  • Dai, Tinglong; Jerath, Kinshuk (2019). "Salesforce Contracting Under Uncertain Demand and Supply: Double Moral Hazard and Optimality of Smooth Contracts". Marketing Science. 38 (5): 852–870. doi:10.1287/mksc.2019.1171.
  • Dai, Tinglong; Cho, Soo-Haeng; Zhang, Fuqiang (2016). "Contracting for On-Time Delivery in the U.S. Influenza Vaccine Supply Chain". Manufacturing & Service Operations Management. 18 (3): 332–346. doi:10.1287/msom.2015.0574.
  • Dai, Tinglong; Jerath, Kinshuk (2013). "Salesforce Compensation with Inventory Considerations". Management Science. 59 (11): 2490–2501. doi:10.1287/mnsc.2013.1809.

Book Chapters

References

  1. ^ a b "Tinglong Dai, PhD | Johns Hopkins Carey Business School". carey.jhu.edu. Retrieved 2021-09-04.
  2. ^ "Research & Beyond - Tinglong Dai". Retrieved 2021-09-05.
  3. ^ a b c "China dominates the pandemic PPE market. What does that mean for U.S. as virus surges?". PBS NewsHour. 2020-10-27. Retrieved 2021-09-05.
  4. ^ a b Dai, Tinglong; Cho, Soo-Haeng; Zhang, Fuqiang (2016-03-30). "Contracting for On-Time Delivery in the U.S. Influenza Vaccine Supply Chain". Manufacturing & Service Operations Management. 18 (3): 332–346. doi:10.1287/msom.2015.0574. ISSN 1523-4614.
  5. ^ a b Mak, Ho-Yin; Dai, Tinglong; Tang, Christopher S. (2021-08-28). "Managing Two-Dose COVID-19 Vaccine Rollouts with Limited Supply: Operations Strategies for Distributing Time-Sensitive Resources". Rochester, NY. doi:10.2139/ssrn.3790836. S2CID 233897837. SSRN 3790836. {{cite journal}}: Cite journal requires |journal= (help)
  6. ^ a b Dai, Tinglong; Song, Jing-Sheng (2021-09-01). "Transforming COVID-19 vaccines into vaccination". Health Care Management Science. 24 (3): 455–459. doi:10.1007/s10729-021-09563-3. ISSN 1572-9389. PMC 8206869. PMID 34132977.
  7. ^ Dai, Tinglong; Tang, Christopher (2021-07-21). "How to Build a Coronavirus Vaccine Supply Chain". Bloomberg Law. Retrieved 2021-09-11.{{cite web}}: CS1 maint: url-status (link)
  8. ^ Dai, Tinglong (2021-02-23). "How to fix the mess of COVID-19 vaccine appointment scheduling". Fast Company. Retrieved 2021-09-11.
  9. ^ Liljenquist, Dan; Dai, Tinglong; Bai, Ge (2021-02-26). "A Nonprofit Public Utility Approach to Enhance Next-Generation Vaccine Manufacturing Capacity". Population Health Management. 24 (5): 546–547. doi:10.1089/pop.2020.0377. ISSN 1942-7891.
  10. ^ "Q&A with Johns Hopkins University professor, the US top vaccine distribution expert". Retrieved 2021-09-05.
  11. ^ a b Allen, Nathan (2021-05-03). "Poets&Quants | Poets&Quants' Best 40-Under-40 Business School Professors Of 2021". Poets&Quants. Retrieved 2021-09-05.
  12. ^ a b Allen, Nathan (2021-05-03). "Poets&Quants | 2021 Best 40-Under-40 Professors: Tinglong Dai, Johns Hopkins University (Carey)". Poets&Quants. Retrieved 2021-09-05.
  13. ^ "Johns Hopkins Discovery Awards: 2015 Awardees". Johns Hopkins University. 2015-07-06. Retrieved 2021-09-11.{{cite web}}: CS1 maint: url-status (link)
  14. ^ "Johns Hopkins Discovery Awards: 2020 Awardees". Johns Hopkins University. 2020-12-07. Retrieved 2021-09-11.{{cite web}}: CS1 maint: url-status (link)
  15. ^ "Johns Hopkins Discovery Awards: 2022 Awardees". VPR at JHU. 2022-05-23. Retrieved 2022-06-01.
  16. ^ "Hopkins Business of Health Initiative". hbhi.jhu.edu. Retrieved 2021-09-05.
  17. ^ "The Institute of Data Intensive Engineering and Science". Retrieved 2021-09-04.{{cite web}}: CS1 maint: url-status (link)
  18. ^ Dai, Tinglong; Tayur, Sridhar (2019-08-01). "OM Forum—Healthcare Operations Management: A Snapshot of Emerging Research". Manufacturing & Service Operations Management. 22 (5): 869–887. doi:10.1287/msom.2019.0778. ISSN 1523-4614. S2CID 169467315.
  19. ^ Dai, Tinglong; Zheng, Ronghuo; Sycara, Katia (2019-08-01). "Jumping the Line, Charitably: Analysis and Remedy of Donor-Priority Rule". Management Science. 66 (2): 622–641. doi:10.1287/mnsc.2018.3266. ISSN 0025-1909. S2CID 54028044.
  20. ^ Wang, Guihua; Zheng, Ronghuo; Dai, Tinglong (2021-07-09). "Does Transportation Mean Transplantation? Impact of New Airline Routes on Sharing of Cadaveric Kidneys". Management Science. 68 (5): 3660–3679. doi:10.1287/mnsc.2021.4103. ISSN 0025-1909. S2CID 237797406.
  21. ^ Dai, Tinglong; Wang, Xiaofang; Hwang, Chao-Wei (2021-07-16). "Clinical Ambiguity and Conflicts of Interest in Interventional Cardiology Decision Making". Manufacturing & Service Operations Management. 24 (2): 864–882. doi:10.1287/msom.2021.0969. ISSN 1523-4614. S2CID 237642935.
  22. ^ Dai, Tinglong; Akan, Mustafa; Tayur, Sridhar (2016-11-14). "Imaging Room and Beyond: The Underlying Economics Behind Physicians' Test-Ordering Behavior in Outpatient Services". Manufacturing & Service Operations Management. 19 (1): 99–113. doi:10.1287/msom.2016.0594. ISSN 1523-4614. S2CID 10713559.
  23. ^ Dai, Tinglong; Singh, Shubhranshu (2020-01-23). "Conspicuous by Its Absence: Diagnostic Expert Testing Under Uncertainty". Marketing Science. 39 (3): 540–563. doi:10.1287/mksc.2019.1201. ISSN 0732-2399. S2CID 214449699.
  24. ^ Bai, Ge; Dai, Tinglong; Rajgopal, Shivaram (2020-07-25). "Commentary: The PPE supply chain is a black box—that needs to change". Fortune. Retrieved 2021-09-05.{{cite web}}: CS1 maint: url-status (link)
  25. ^ Dai, Tinglong; Bai, Ge; Anderson, Gerard F. (2020-09-01). "PPE Supply Chain Needs Data Transparency and Stress Testing". Journal of General Internal Medicine. 35 (9): 2748–2749. doi:10.1007/s11606-020-05987-9. ISSN 0884-8734. PMC 7326307. PMID 32607934.
  26. ^ Dai, Tinglong; Zaman, Muhammad H.; Padula, William V.; Davidson, Patricia M. (2021-01-01). "Supply chain failures amid Covid‐19 signal a new pillar for global health preparedness". Journal of Clinical Nursing. 30 (1–2). doi:10.1111/jocn.15400. ISSN 0962-1067. PMC 7361462. PMID 32620038.
  27. ^ Dai, Tinglong (2020-07-15). "Where does your PPE come from? A lack of transparency is hurting Americans". Fast Company. Retrieved 2021-09-05.
  28. ^ "The U.S. Medical Supply Chain Isn't Ready for a Second Wave". MarketWatch. Retrieved 2021-09-05.
  29. ^ Dai, Tinglong; Tang, Christopher (2020-05-27). "EETimes - Needed: A PPE Industrial Commons". EETimes. Retrieved 2021-09-05.{{cite web}}: CS1 maint: url-status (link)
  30. ^ "Not Much Progress on PPE 'Reshoring'". www.medpagetoday.com. 2020-09-25. Retrieved 2021-09-05.
  31. ^ Morris, David (2021-04-23). "COVID exposed global supply chain flaws. Can Biden bring manufacturing back to the U.S.?". Fortune. Retrieved 2021-09-05.{{cite web}}: CS1 maint: url-status (link)
  32. ^ Dai, Tinglong; Ke, Rongzhu; Ryan, Christopher Thomas (2020-08-04). "Incentive Design for Operations-Marketing Multitasking". Management Science. 67 (4): 2211–2230. doi:10.1287/mnsc.2020.3651. ISSN 0025-1909. S2CID 234602078.
  33. ^ Dai, Tinglong; Jerath, Kinshuk (2019-08-28). "Salesforce Contracting Under Uncertain Demand and Supply: Double Moral Hazard and Optimality of Smooth Contracts". Marketing Science. 38 (5): 852–870. doi:10.1287/mksc.2019.1171. ISSN 0732-2399.
  34. ^ Dai, Tinglong; Jerath, Kinshuk (2016-01-11). "Technical Note—Impact of Inventory on Quota-Bonus Contracts with Rent Sharing". Operations Research. 64 (1): 94–98. doi:10.1287/opre.2015.1461. ISSN 0030-364X.
  35. ^ Dai, Tinglong; Jerath, Kinshuk (2013-09-16). "Salesforce Compensation with Inventory Considerations". Management Science. 59 (11): 2490–2501. doi:10.1287/mnsc.2013.1809. ISSN 0025-1909.
  36. ^ "Handbook of Healthcare Analytics: Theoretical Minimum for Conducting 21st Century Research on Healthcare Operations | Wiley". Wiley.com. Retrieved 2021-09-05.
  37. ^ "Hunt for vaccine slots often leads through scheduling maze". AP NEWS. 2021-04-20. Retrieved 2021-09-05.
  38. ^ "Vaccine storage issues could leave 3B people without access". AP NEWS. 2021-04-20. Retrieved 2021-09-05.
  39. ^ "States Craft Vaccine Plans in a Haze of Changing Information". Bloomberg.com. 2020-12-04. Retrieved 2021-09-05.
  40. ^ Madhok, Diksha. "India's Covid-19 catastrophe could hurt global supplies of medicines, clothing and shoes". CNN. Retrieved 2021-09-05.
  41. ^ Isidore, Chris (13 March 2021). "Here's what Covid vaccines are worth to Big Pharma". CNN. Retrieved 2021-09-05.
  42. ^ "COVID exposed global supply chain flaws. Can Biden bring manufacturing back to the U.S.?". Fortune. Retrieved 2021-09-05.
  43. ^ "Karen Lynch got the big job at CVS. Now comes the big challenge: Vaccinate America". Fortune. Retrieved 2021-09-05.
  44. ^ "With billions spent and 'wartime' declared, why are vaccines still in short supply?". Fortune. Retrieved 2021-09-05.
  45. ^ "Pfizer's extra vaccine dose is more of a mess than a miracle". Fortune. Retrieved 2021-09-05.
  46. ^ "Pfizer's COVID vaccine comes with a chilly complication. But that may change". Fortune. Retrieved 2021-09-05.
  47. ^ Pérez-Peña, Richard (2021-05-03). "How Hard Could It Be to Vaccinate the Whole World? This Hard". The New York Times. ISSN 0362-4331. Retrieved 2021-09-05.
  48. ^ Robbins, Rebecca (2021-04-05). "Walgreens Not Following U.S. Guidance on Pfizer Vaccine Spacing". The New York Times. ISSN 0362-4331. Retrieved 2021-09-05.
  49. ^ Shear, Michael D.; Jewett, Christina; Swanson, Ana (2022-05-19). "Big Questions Remain About White House Plan to Speed Formula to Shelves". The New York Times. ISSN 0362-4331. Retrieved 2022-05-20.
  50. ^ Goldberg, Emma; Hirsch, Lauren; McCabe, David (2022-01-12). "Why Some Workers Are Getting All the Covid Tests They Need". The New York Times. ISSN 0362-4331. Retrieved 2022-05-20.
  51. ^ Swanson, Ana (2022-01-12). "Supply chain snags continued to drive up prices in December". The New York Times. ISSN 0362-4331. Retrieved 2022-05-20.
  52. ^ Sorkin, Andrew Ross; Karaian, Jason; Kessler, Sarah; Gandel, Stephen; Merced, Michael J. de la; Hirsch, Lauren; Livni, Ephrat (2022-01-06). "How Corporate America Has Changed After the Capitol Attack". The New York Times. ISSN 0362-4331. Retrieved 2022-05-20.
  53. ^ Smialek, Jeanna; Swanson, Ana (2022-01-12). "Consumer prices popped again in December, casting a shadow over the economy". The New York Times. ISSN 0362-4331. Retrieved 2022-05-20.
  54. ^ Shear, Michael D.; Jewett, Christina; Swanson, Ana (2022-05-19). "Big Questions Remain About White House Plan to Speed Formula to Shelves". The New York Times. ISSN 0362-4331. Retrieved 2022-06-01.
  55. ^ "Bad Batch Of Johnson & Johnson Vaccines Sets Back Production". NPR.org. Retrieved 2021-09-05.
  56. ^ Weise, Elizabeth. "'Mind-bogglingly complex': Here's what we know about how COVID-19 vaccine will be distributed when it's approved". USA TODAY. Retrieved 2021-09-05.
  57. ^ Miller, Ryan W. "How will you be told when it's your turn for a COVID-19 vaccine? It's complicated". USA TODAY. Retrieved 2021-09-05.
  58. ^ Weise, Elizabeth. "'Vaccine angels' can only do so much: US struggles to make it easier to find COVID-19 vaccination appointments". USA TODAY. Retrieved 2021-09-05.
  59. ^ Loftus, Peter; Burton, Thomas (2021-04-01). "FDA Probes Cause of Failed Johnson & Johnson Covid-19 Vaccine Batch". Wall Street Journal. ISSN 0099-9660. Retrieved 2021-09-05.
  60. ^ Witte, Griff (2021-02-03). "Some states are racing ahead of others with their coronavirus vaccine rollouts. Their secret? Keeping it simple". Washington Post. Retrieved 2021-09-04.
  61. ^ "Biden pledges to fight new variant 'with science and speed,' as omicron cases multiply and winter outlook worsens". Washington Post. ISSN 0190-8286. Retrieved 2021-12-18.
  62. ^ "Here's how the distribution infrastructure will deploy coronavirus vaccine". CNBC. 2020-11-09. Retrieved 2021-09-05.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Tinglong_Dai&oldid=1104572945"